SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-021944
Filing Date
2023-05-15
Accepted
2023-05-15 07:00:25
Documents
14
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K verv-20230515.htm   iXBRL 8-K 60994
2 EX-99.1 verv-ex99_1.htm EX-99.1 146255
3 GRAPHIC img74140242_0.jpg GRAPHIC 2993
  Complete submission text file 0000950170-23-021944.txt   350731

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20230515_lab.xml EX-101.LAB 18527
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20230515_pre.xml EX-101.PRE 11558
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20230515.xsd EX-101.SCH 2471
8 EXTRACTED XBRL INSTANCE DOCUMENT verv-20230515_htm.xml XML 4714
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 23918322
SIC: 2834 Pharmaceutical Preparations